Insys Therapeutics Issues Statement on Its Use of Specialty Pharmacies

(firmenpresse) - PHOENIX, AZ -- (Marketwired) -- 10/26/15 -- Insys Therapeutics, Inc. (NASDAQ: INSY) ("Insys" or "the Company") today issued a statement on the Company's use of specialty pharmacies:

Insys distributes Subsys through both specialty and traditional retail pharmacies. All pharmacies that fulfill Subsys prescriptions are fully independent.

The Company's relationships with every pharmacy that fulfills Subsys prescriptions are non-exclusive, in that each of these pharmacies may also fulfill prescriptions for other pharmaceutical manufacturers.

Insys does not own or have any ownership interest in any pharmacy and does not possess an option to acquire any pharmacy.

Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. Using proprietary sublingual spray technology and capabilities to develop pharmaceutical cannabinoids, Insys addresses the clinical shortcomings of existing commercial products. Insys currently markets two products: Subsys® (fentanyl sublingual spray), and a generic version of Dronabinol (THC) capsules. The Company recently submitted a New Drug Application to the U.S. Food and Drug Administration for Dronabinol Oral Solution, a proprietary, orally administered liquid formulation of dronabinol that Insys believes has distinct advantages over the current formulation of dronabinol in soft gel capsule. Insys is developing a pipeline of sublingual sprays, as well as pharmaceutical cannabidiol.

Subsys® is a registered trademark of Insys Therapeutics, Inc.

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: Marketwired
Datum: 26.10.2015 - 18:56 Uhr
Sprache: Deutsch
News-ID 429435
Anzahl Zeichen: 0

contact information:
Town:

PHOENIX, AZ

Kategorie:

Drugs

Diese Pressemitteilung wurde bisher 258 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Insys Therapeutics Issues Statement on Its Use of Specialty Pharmacies"
steht unter der journalistisch-redaktionellen Verantwortung von

Insys Therapeutics (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Insys Therapeutics Announces Its Naloxone Sublingual Spray Received Fast Track D ...

PHOENIX, AZ -- (Marketwired) -- 10/29/15 -- Insys Therapeutics, Inc. (NASDAQ: INSY) ("Insys" or "the Company") today announced that the U.S. Food and Drug Administration ("FDA") has granted Fast Track designation to its ...

Insys Therapeutics to Report Third Quarter 2015 Results ...

PHOENIX, AZ -- (Marketwired) -- 10/22/15 -- Insys Therapeutics, Inc. (NASDAQ: INSY) today announced that the Company will release its financial results for the third quarter 2015 on Thursday, November 5, 2015, before the U.S. financial markets open. ...

Insys Therapeutics In-Licenses Cannabinoid Inhalation Technology ...

PHOENIX, AZ -- (Marketwired) -- 09/24/15 -- Insys Therapeutics, Inc. (NASDAQ: INSY) today announced that it has entered into an exclusive license agreement and partnership with U.K. based Senzer Ltd. for the development of inhaled synthetic pharmace ...

Alle Meldungen von Insys Therapeutics